Aaron Mitchell, MD, MPH

Assistant Attending
Aaron Mitchell, MD, MPH

Office Phone


Dr. Mitchell is an oncologist and health services researcher. He did his clinical training at Duke University Hospital (Residency, internal medicine) and at University of North Carolina at Chapel Hill (Fellowship, medical oncology). He received an MPH in epidemiology from the University of North Carolina and completed a postdoctoral research fellowship at UNC’s Cecil G. Sheps Center for Health Services Research. His research interests are in understanding the interaction between financial incentives and physician behavior. He seeks to understand how changes to current reimbursement models for oncology services may be used to achieve better patient outcomes and reduce low-value care. He previously led an ASCO-funded observational study to assess oncologists’ responsiveness to reimbursement incentives in using high-cost, low-efficacy drugs, and he continues to study physician-level factors associated with use of low-value treatments. His current projects include 1) Assessing the delivery of guideline-preferred treatments across cancer types, measuring the frequency with which patients receive non-preferred treatments, and identifying patient and provider characteristics associated with non-preferred treatments; 2) Measuring financial conflicts of interest among oncologists, and the influence of these conflicts on clinical practice and guideline recommendations; and 3) Seeking to understand and improve the appropriate use of supportive care medications for prostate cancer patients. His clinical interests are in genitourinary malignancies. He holds a co-appointment in the Genitourinary Oncology Service, treating patients with prostate and bladder cancer.


  1. 1) Mitchell AP, Winn AN, Dusetzina SB. Pharmaceutical Industry Payments and Oncologists’ Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Intern Med. 2018 Jun 1;178(6):854-856. doi: 10.1001/jamainternmed.2018.0776. PubMed PMID: 29630687.
  2. 2) Mitchell AP, Basch EM, Dusetzina SB. Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. JAMA Oncol. 2016 Dec 1;2(12):1628-1631. doi: 10.1001/jamaoncol.2016.2710. PubMed PMID: 27561170.
  3. 3) Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR. Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. J Oncol Pract. 2015 Nov;11(6):491-7. doi: 10.1200/JOP.2015.004929. Epub 2015 Sep 1. PubMed PMID: 26330533.
  4. 4) Mitchell A, Muluneh B, Patel R, Basch E. Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics. J Oncol Pharm Pract. 2017 Jan 1:1078155217719585. doi: 10.1177/1078155217719585. [Epub ahead of print] PubMed PMID: 28714357.
  5. 5) Mitchell AP, Hirsch BR, Harrison MR, Abernethy AP, George DJ. Deferred systemic therapy in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun;13(3):e159-66. doi: 10.1016/j.clgc.2014.12.017. Epub 2014 Dec 31. PubMed PMID: 25770767.

View a full listing of Aaron Mitchell’s journal articles.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Aaron Mitchell discloses the following relationships and financial interests:

  • Institute for Clinical and Economic Review
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures